- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 16
- States / cities
- Duarte, California • La Jolla, California • Long Beach, California + 10 more
Location Directory
Clinical trials in Nashville, Tennessee
This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10880
Shown on this page
12
Current sort
Recently updated
Location scope
Nashville, TN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 721–732 of 10,880 matching trials in Nashville, TN.
Live ClinicalTrials.gov results.
Institutions in Nashville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- HR+/HER2- Breast Cancer
- Interventions
- BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2037
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 79 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- HER3-DXd, Osimertinib
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 13
- States / cities
- Santa Monica, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
- Interventions
- ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin, mFOLFIRINOX, GnP, Midazolam
- Drug
- Lead sponsor
- Alterome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 14
- States / cities
- Orlando, Florida • Tampa, Florida • Boston, Massachusetts + 7 more
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Interventions
- AADvac1, Tau2
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • San Francisco, California • Lexington, Kentucky + 4 more
- Conditions
- Rett Syndrome, RTT, Rett Syndrome, Atypical
- Interventions
- EEG and Auditory and Visual Evoked Potentials (AEP and VEP), Clinical assessment
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Year to 18 Years · Female only
- Enrollment
- 222 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Brookline, Massachusetts + 3 more
- Conditions
- Dystonia
- Interventions
- VIM0423, VIM0423 Placebo
- Drug
- Lead sponsor
- Vima Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 35 more
- Conditions
- Overweight , Obesity, Adults
- Interventions
- ALV-100, Placebo
- Drug
- Lead sponsor
- Alveus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 16 more
- Conditions
- Gastrointestinal Tract Malignancies
- Interventions
- Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Non Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia
- Interventions
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101
- Genetic
- Lead sponsor
- Vironexis Biotherapeutics Inc.
- Industry
- Eligibility
- 13 Years to 90 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Interventions
- AADvac1, Donanemab
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • San Francisco, California • Lexington, Kentucky + 4 more